NCT06712121View on ClinicalTrials.gov

Venetoclax and Decitabine in R/R T-ALL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions
T Lymphoblastic Leukemia/Lymphoma
Interventions
DRUG

decitabine plus venetoclax

decitabine 20mg/m2 for 7 days venetoclax 400mg daily for 21 days

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Korean Society of Hematology

NETWORK

lead

Seoul National University Hospital

OTHER